This conversation revolves around the challenges posed by histopathology’s flaws. Scott Friedman reminds us that NAFLD Activity scores do not correlate with outcomes, Roger Green reminds us that coder reliability scores would not be accepted in marketing research and Stephen Harrison describes the impact of these flaws on investors and drug/device companies. In the end, Scott provides a peak at some of the topics his lab is exploring and the entire panel discusses what they consider key takeaways from this engrossing episode.